Once-weekly DPP-4 inhibitor, ‘omarigliptin,’ to be launched in the domestic market

A once-weekly DPP-4 inhibitor diabetes treatment will enter the domestic market.

According to the industry concerned on the 21^st, MSD Korea has prepared for the domestic launch of a DPP-4 inhibitor using ‘omarigliptin’ as the main substance.

The drug, a once-weekly oral diabetes-treating DPP-4 inhibitor, was recently launched in Japan in the product name of ‘Marizev.’ In Japan, Takeda’s ‘trel...